68 related articles for article (PubMed ID: 18279418)
1. Three-year follow-up of malignancies in tacrolimus-treated renal recipients--an analysis of European multicentre studies.
Cowlrick I; Delventhal H; Kaipainen K; Krcmar C; Petan J; Schleibner S
Clin Transplant; 2008; 22(3):372-7. PubMed ID: 18279418
[TBL] [Abstract][Full Text] [Related]
2. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil.
Washburn K; Speeg KV; Esterl R; Cigarroa F; Pollack M; Tourtellot C; Maxwell P; Halff G
Transplantation; 2001 Nov; 72(10):1675-9. PubMed ID: 11726831
[TBL] [Abstract][Full Text] [Related]
3. [Daclizumab in combination with mycophenolate mofetil and a late introduction of Tacrolimus at low doses, as a therapeutic approach in the elderly renal transplant donor-recipients pairs in kidney transplant].
Gentil MA; Osuna A; Capdevilla L; Cantarell C; Pereira P; Mazuecos A; González Molina M
Nefrologia; 2008; 28(3):287-92. PubMed ID: 18590495
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients.
Pescovitz MD; Knechtle S; Alexander SR; Colombani P; Nevins T; Nieforth K; Bouw MR
Pediatr Transplant; 2008 Jun; 12(4):447-55. PubMed ID: 18466432
[TBL] [Abstract][Full Text] [Related]
5. Results of one-year follow-up of steroid-free immunosuppression in pediatric renal transplant patients.
Silverstein DM; Aviles DH; LeBlanc PM; Jung FF; Vehaskari VM
Pediatr Transplant; 2005 Oct; 9(5):589-97. PubMed ID: 16176415
[TBL] [Abstract][Full Text] [Related]
6. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study.
Klintmalm GB; Washburn WK; Rudich SM; Heffron TG; Teperman LW; Fasola C; Eckhoff DE; Netto GJ; Katz E
Liver Transpl; 2007 Nov; 13(11):1521-31. PubMed ID: 17969201
[TBL] [Abstract][Full Text] [Related]
7. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber LW; Gaber AO
Transpl Int; 2001 Dec; 14(6):396-404. PubMed ID: 11793037
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids.
Hesselink DA; Ngyuen H; Wabbijn M; Gregoor PJ; Steyerberg EW; van Riemsdijk IC; Weimar W; van Gelder T
Br J Clin Pharmacol; 2003 Sep; 56(3):327-30. PubMed ID: 12919182
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
10. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
Miura M; Harada H; Fukuzawa N; Iwami D; Taniguchi A; Seki T; Togashi M; Ogawa Y; Satoh H; Hirano T
Clin Transplant; 2005; 19 Suppl 14():54-8. PubMed ID: 15955170
[TBL] [Abstract][Full Text] [Related]
11. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppression in HCV-positive liver-transplant recipients.
Chan AJ; Lake JR
Curr Opin Organ Transplant; 2012 Dec; 17(6):648-54. PubMed ID: 23128793
[TBL] [Abstract][Full Text] [Related]
13. Rescue immunosuppressive therapies in living-related renal allotransplant: a long-term prospective randomized evaluation.
Bakr MA; Gheith OA; Ismael AM; Baz ME; Shehab El-Dein AB; Ghoneim MA
Exp Clin Transplant; 2008 Mar; 6(1):48-53. PubMed ID: 18405245
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
Yoshida EM; Marotta PJ; Greig PD; Kneteman NM; Marleau D; Cantarovich M; Peltekian KM; Lilly LB; Scudamore CH; Bain VG; Wall WJ; Roy A; Balshaw RF; Barkun JS
Liver Transpl; 2005 Sep; 11(9):1064-72. PubMed ID: 16123958
[TBL] [Abstract][Full Text] [Related]
15. Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study.
Braconnier P; Del Marmol V; Broeders N; Kianda M; Massart A; Lemy A; Ghisdal L; Le Moine A; Madhoun P; Racapé J; Abramowicz D; Wissing KM
Nephrol Dial Transplant; 2012 Jun; 27(6):2547-53. PubMed ID: 22123748
[TBL] [Abstract][Full Text] [Related]
16. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
Nematalla AH; Bakr MA; Gheith OA; Elagroudy AE; Elshahawy el-M; Aghoneim M
Exp Clin Transplant; 2007 Dec; 5(2):673-9. PubMed ID: 18194120
[TBL] [Abstract][Full Text] [Related]
17. Use of different immunosuppressive strategies in recipients of kidneys from nonheart-beating donors.
Sánchez-Fructuoso AI; Marques M; Conesa J; Ridao N; Rodríguez A; Blanco J; Barrientos A
Transpl Int; 2005 May; 18(5):596-603. PubMed ID: 15819810
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
Liu CL; Fan ST; Lo CM; Chan SC; Ng IO; Lai CL; Wong J
Liver Transpl; 2004 Jun; 10(6):728-33. PubMed ID: 15162466
[TBL] [Abstract][Full Text] [Related]
19. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
Sarwal MM; Vidhun JR; Alexander SR; Satterwhite T; Millan M; Salvatierra O
Transplantation; 2003 Nov; 76(9):1331-9. PubMed ID: 14627912
[TBL] [Abstract][Full Text] [Related]
20. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era.
Ciancio G; Siquijor AP; Burke GW; Roth D; Cirocco R; Esquenazi V; Byrne GE; Miller J
Clin Transplant; 1997 Jun; 11(3):243-9. PubMed ID: 9193850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
